ArticleBMC infectious diseases2026
Type 2 diabetes mellitus wake-up call: fatal streptococcal toxic shock syndrome triggered by the M1(UK) Streptococcus pyogenes - a case report with genomic insights.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
introductionStreptococcus pyogenes (S. pyogenes) can cause streptococcal toxic shock syndrome (STSS), especially in immunocompromised individuals. Early diagnosis is the key to treat STSS effectively. This study presents a fatal case of STSS caused by the emerging M1(UK) S. pyogenes lineage in a patient with type 2 diabetes mellitus (T2DM), alongside a comprehensive literature review. CASE PRESENTATION: A 65-year-old man with T2DM presented with altered consciousness, necrotizing soft tissue injury and was diagnosed with STSS. Bacterial cultures were obtained from right lower limb exudate, right hand mass pus and scrotal pus. Antimicrobial susceptibility testing (AST), whole-genome sequencing (WGS), phylogenomic analysis, and virulence profiling were performed. S. pyogenes isolates from all sites were identified as M1(UK) (emm1/ST28) lineage, closely related to UK strains. The strain was resistant to tetracycline, erythromycin, and clindamycin (ermB, tetM, lmrP) but remained susceptible to β-lactams. Key virulence genes included slo, speC/speG, hasABC and scpA. The slo-mediated endothelial lysis and speC/G-induced cytokine storm contributed to capillary leakage and rapid clinical deterioration. Increased hasABC-mediated capsule expression under hyperglycemia further impaired bacterial clearance.
conclusionThis case highlights the threat of antimicrobial-resistant M1(UK) S. pyogenes in patient with T2DM. The pathogenicity of strain was driven by cytolytic toxins, superantigens, and immune evasion. Early STSS diagnosis is facilitated by microscopic examination and rapid antigen detection test (RADT) of group A streptococcus. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.